A kidney drug slowed disease in patients who don’t even have diabetes

Chronic kidney disease has long been treated most aggressively when it stems from diabetes, the condition behind a large share of cases. But more than half of the world’s kidney patients develop the disease for other reasons, and they have had far fewer proven options to slow it down. A large clinical trial has now shown that a drug already used in diabetic kidney disease can also protect the kidneys of people who do not have diabetes, a result that could widen who qualifies for the medicine.

The drug is finerenone, sold under the brand name Kerendia, and the study is called FIND-CKD. Its central finding is that adding the drug to standard care meaningfully slowed the loss of kidney function and reduced the combined risk of serious heart and kidney events, compared with a placebo. Researchers described it as the largest trial to date dedicated specifically to non-diabetic chronic kidney disease.

What the FIND-CKD trial tested

The trial enrolled more than 1,500 adults with chronic kidney disease from a range of underlying causes other than diabetes, including kidney damage linked to high blood pressure and a group of conditions known as glomerular diseases. Participants were randomly assigned to receive either finerenone or a placebo on top of the current standard of care, which included the maximum tolerated dose of a renin-angiotensin system blocker, the class of blood-pressure and kidney-protective drugs that has anchored treatment for years. That design matters because it tested whether the new drug adds benefit beyond what patients already receive, not whether it beats nothing at all.

According to a research announcement from the European Renal Association, the results were presented as late-breaking findings at the group’s 63rd Congress in Glasgow in June 2026 and published simultaneously in the New England Journal of Medicine. Finerenone belongs to a category called non-steroidal, selective mineralocorticoid receptor antagonists, which work differently from the older steroidal drugs that target the same receptor and tend to cause more side effects.

Slowing the decline in kidney function

The trial’s main measure was the annual rate of change in estimated glomerular filtration rate, or eGFR, a standard gauge of how well the kidneys filter waste from the blood. As kidney disease progresses, that rate steadily falls, and the slope of the decline predicts how soon a patient may face kidney failure. The study met its primary endpoint: compared with placebo, finerenone slowed the yearly decline in eGFR by 0.7 milliliters per minute per 1.73 square meters, a difference the investigators reported as statistically significant.

A fraction of a milliliter per year may sound modest, but over the many years that chronic kidney disease unfolds, a gentler slope can add up to meaningfully more preserved function and delay the point at which dialysis or a transplant becomes necessary. The lead investigator, a clinical trialist at the University Medical Center Groningen in the Netherlands, said the benefit appeared consistent across the different patient subgroups studied, which supports applying it broadly across the varied causes of non-diabetic kidney disease.

A lower risk of heart and kidney events

Beyond the filtration measure, the trial tracked a combined secondary outcome bundling several of the worst events a kidney patient can face: kidney failure, a sustained steep drop in filtration, hospitalization for heart failure, or death from cardiovascular causes. Finerenone reduced the risk of that composite by 23 percent relative to placebo. The heart-kidney link is central to why the result carries weight, because patients with advanced non-diabetic kidney disease face a sharply elevated chance of a fatal cardiovascular event, not only of kidney failure itself.

Safety followed the pattern seen in the drug’s earlier studies, with no new warning signs. The most closely watched risk with this class is hyperkalemia, an excess of potassium in the blood, and it did occur more often with finerenone than with placebo. But the investigators reported that few of those cases led patients to stop treatment or required hospitalization, and rates of acute kidney injury were similar in both groups. The full peer-reviewed results were published in the New England Journal of Medicine alongside the conference presentation.

Why non-diabetic kidney disease has lagged

Chronic kidney disease affects roughly 850 million people worldwide, and the drug’s maker has noted that more than half of them have forms unrelated to diabetes. Yet those non-diabetic causes, chief among them hypertension and glomerular conditions such as immunoglobulin A nephropathy, have historically been underrepresented in the large trials that shape treatment guidelines. That gap left clinicians extrapolating from studies done mostly in diabetic patients, or relying on the decades-old renin-angiotensin blockers as the main tool.

The manufacturer, which first reported that the trial had met its primary endpoint in March 2026, has said it plans to submit the data to regulators to expand the drug’s approved uses to this population; finerenone is already cleared in more than 100 countries for kidney disease tied to type 2 diabetes. The compound has now posted positive results across several large studies spanning heart failure and different forms of kidney disease, part of a broad development program. For patients with non-diabetic kidney disease and their doctors, FIND-CKD offers something that has been scarce: dedicated, high-quality evidence that a specific therapy can slow their particular version of the disease. Whether that evidence translates into wider prescribing will depend on how regulators act on the filing and how treatment guidelines incorporate the results, a process that typically unfolds over many months. In the meantime, the trial gives specialists a firmer basis for discussing the drug with patients whose kidney disease has no connection to diabetes at all.

This article was produced with AI assistance and reviewed by Morning Overview editors.

More from Morning Overview